CASE REPORT Open Access



Widespread presentation of brown tumors mimicking multiple myeloma

Julien Duyck^{1,5*}, Katrien Spincemaille², Jan Verfaillie³, Caressa Meert⁴ and Kristoff Muylle¹

*Correspondence: julienduyck77@gmail.com

¹ Department of Nuclear Medicine, AZ Delta, Roeselare, Belgium

Department of Endocrinology,
AZ Delta, Roeselare, Belgium
Department of Otolaryngology,
AZ Delta, Roeselare, Belgium
Department of Hematology,
AZ

Delta, Roeselare, Belgium ⁵ Beselare, Belgium

Abstract

Brown tumors or osteitis fibrosa cystica has become a rare presentation of primary hyperparathyroidism in up-to-date clinical practice. Here, we describe a case of longstanding untreated hyperparathyroidism presenting itself with brown tumors in a 65-year-old patient. During the diagnostic work-up of this patient, bone SPECT/CT and ¹⁸F-FDG-PET/CT revealed multiple widespread osteolytic lesions. Differentiating from other bone tumors such as multiple myeloma is challenging. In this case, the final diagnosis was made by integrating the medical history, biochemical diagnosis of primary hyperparathyroidism, pathological findings and medical imaging.

Keywords: Brown tumors, Osteitis fibrosa cystica, Primary parahyperthyroidism, FDG-PET/CT, Bone SPECT/CT, ^{99m}Tc-sestamibi scintigraphy

Main text

A 65-year-old female patient was referred to the orthopedics department with complaints of pain in both legs.

After clinical examination, a bone scintigraphy with SPECT-CT (Figs. 1A/2A) was performed, revealing multiple osteolytic lesions with associated, variable (predominantly moderate) osteoblastic activity in the axial and peripheral skeleton affecting the skull (left maxillary sinus), the left scapula and bilateral lesions in the ribs, pelvis, femur and tibia. The focal higher osteoblastic activity in the right tibia might be related to an associated microfracture. A blood sample showed hypercalcemia (3.86 mmol/L; normal range 2.20–2.55) and increased alkaline phosphatase (240 U/L; normal range: 35–105) with normal blood cell counts, a preserved renal function and the absence of monoclonal antibodies in serum.

Further work-up with ¹⁸F-FDG-PET/CT (Figs. 1B/2B) confirmed the presence of multiple osteolytic lesions, all hypermetabolic and some with cortical breakthrough and expansile growth, compatible with osteolytic bone metastases or a non-secretory myeloma. Compared to bone SPECT/CT, ¹⁸F-FDG-PET/CT was more sensitive for depicting small bone lesions (e.g. in ribs) and allowed a better discrimination of disease related lesions from reactive bone remodeling, for example, nearby the left shoulder prothesis.

A CT-guided biopsy of an osteolytic lesion in the right tibia showed tumoral tissue rich in osteoclast type giant cells. This finding in combination with hypercalcemia



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.




Fig. 1 Whole body bone scintigraphy (anterior and posterior view; **A**) and 18 F-FDG-PET/CT (maximum intensity projection; **B**)

and hyperparathyroidism in a new blood test (PTH: 1121 ng/L; normal range: 15–65) as well as the imaging results lead to a diagnosis of so-called brown tumors.

Review of the patients' medical history revealed that the patient had been referred to an endocrinologist 14 years earlier (in 2008) because of hypercalcemia found in a routine blood test. Since PTH was elevated (231 pg/ml, normal 15–65 pg/ml) and hypocalciuric hypercalcemia was excluded, primary hyperparathyroidism was suspected. A supra-centimetric parathyroid adenoma posterior from the left thyroid lobe was identified by imaging with a planar ^{99m}Tc-sestamibi scintigraphy and echography. Although the patient was referred to the surgery department for a parathyroidectomy, the patient was lost to follow-up and the surgery never took place.

A dual isotope 123 I/ 99m Tc-sestamibi SPECT/CT (Fig. 3) and echography was repeated, confirming the presence of a parathyroid adenoma posterior from the left thyroid lobe. After surgical resection of the parathyroid adenoma (dimensions: 24×18 mm), PTH and calcium in serum normalized. Given the osteoporosis (confirmed by a bone density scan; T-score: -3.4 at the proximal femur) secondary to the longstanding hyperparathyroidism, a treatment with biphosphonates (zoledronic acid 4 mg) is administered every 4 weeks.




Fig. 2 Comparison of the presentation of 3 bone lesions on bone SPECT/CT (upper row; $\bf A$) and 18 F-FDG-PET/CT (lower row; $\bf B$), respectively, in the skull (left maxillary sinus), a rib and the right femur




Fig. 3 A dual isotope 123 I/ 99m Tc-sestamibi SPECT/CT confirmed the presence of a 99m Tc-sestamibi-avid nodule (lower row; **B**, without 123 I-uptake upper row; **A**) posterior from the left thyroid lobe

Conclusion

Brown tumors are degenerative cystic formations caused by persistent hyperparathyroidism. These usually are the end stage lesions of constantly elevated parathyroid hormone (PTH) (Chew and Huang-Hellinger 1993; Vanitcharoenkul et al. 2021; Bilezikian et al. 2005; Silverberg and Bilezikian 1996). These have become increasingly rare to find because of the early detection of hyperparathyroidism due to routine biochemical screening (Vanitcharoenkul et al. 2021; Bilezikian et al. 2005; Silverberg and Bilezikian 1996; Pappu et al. 2016; Liu et al. 2013). Radiologically these tumors present as lytic lesions or multilobular cystic changes of the bone (Misiorowski et al. 2017). The differential diagnosis with other bone tumors such as osteolytic bone metastasis, multiple myeloma, bone cysts and giant-cell tumor can be challenging by medical imaging alone (Van der Woude and Smithuis 2010; Kalathas et al. 2010). Although nowadays it has become a rare imaging finding, osteitis fibrosa cystica should be considered in the differential diagnosis in patients presenting osteolytic lesions particularly with cortical breakthrough, expansile growth and hypermetabolic features on ¹⁸F-FDG-PET/CT. Incorporation of pathological findings and biochemical analysis—showing high PTH, high calcium and low phosphate—is needed to diagnose brown tumors in the context of longstanding hyperparathyroidism (Misiorowski et al. 2017; Van der Woude and Smithuis 2010).

Acknowledgements

No acknowledgments to be made.

Author contributions

DJ wrote this case report. MK provided the imaging material and helped finalize the main manuscript. All other authors provided the necessary information for writing this case report. All authors read and approved the final manuscript.

Funding

No funding to declare.

Availability of data and materials

No data or material was interpreted for this case report.

Declarations

Ethics approval and consent to participate

No ethical approval was needed for this case report.

Consent for publication

Consent was obtained from the concerning patient.

Competing interests

No competing interests to declare.

Received: 12 April 2023 Accepted: 25 May 2023

Published online: 08 June 2023

References

Bilezikian J, Brandi M, Rubin M, Silverberg S (2005) Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 257(1):6–17

Chew FS, Huang-Hellinger F (1993) Brown tumor. Am J Roentgenol 160:752–752

Kalathas T, Kalatha T, Boultoukas E (2010) Brown tumors; a possible pitfall in diagnosing metastatic disease. Hell J Nucl Med 13(1):15–17

Liu J, Cusano N, Silva B, Zhao L, He X, Tao B et al (2013) Primary hyperparathyroidism: a tale of two cities revisited—New York and Shanghai. Bone Res 1(2):162–169

Misiorowski W, Czajka-Oraniec I, Kochman M, Zgliczyński W, Bilezikian J (2017) Osteitis fibrosa cystica—a forgotten radiological feature of primary hyperparathyroidism. Endocrine 58(2):380–385

Pappu R, Jabbour S, Regianto A, Reginato A (2016) Musculoskeletal manifestations of primary hyperparathyroidism. Clin Rheumatol 35(12):3081–3087

- Silverberg S, Bilezikian J (1996) Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 81(6):2036–2040
- Vanitcharoenkul E, Singsampun N, Unnanuntana A, Sirinvaravong S (2021) Osteitis fibrosa cystica and pathological fractures—the classic but neglected skeletal manifestation of primary hyperparathyroidism: a case report. BMC Musculoskelet Disord 22(1):443
- Van der Woude HJ, Smithuis R (2010) Bone tumor—systematic approach and differential diagnosis. Radiologyassistant. http://www.radiologyassistant.nl/en/p494e15cbf0d8d/bone-tumor-systematic-approach-and-differential-diagnosis.html

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- ► Convenient online submission
- ► Rigorous peer review
- ▶ Open access: articles freely available online
- ► High visibility within the field
- ► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com